quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 3, 2026

Beiersdorf Aktiengesellschaft Q4 Earnings Call Highlights

View original at finance.yahoo.com
Beiersdorf Aktiengesellschaft Q4 Earnings Call Highlights Beiersdorf Aktiengesellschaft logo Beiersdorf Aktiengesellschaft (ETR:BEI) management said the company delivered “stable” full-year 2025 results in a difficult operating backdrop, while outlining steps to restore momentum at its largest brand, NIVEA, and reaffir…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Beiersdorf maintained its position as the best performing skincare company globally for the third year in a row

    80% confidence
  • NIVEA's 2025 performance fell short of expectations due to market slowdown, China repositioning, and major innovations concentrated in second half

    80% confidence
  • Cash conversion was weaker than hoped and working capital rose above 10% of sales

    80% confidence
  • NIVEA Cellular Epigenetic Serum remains the number one serum across Europe

    80% confidence
  • The luxury market remains highly volatile with persistent weakness in the U.S. and travel retail

    80% confidence
  • NIVEA Cellular Epigenetic Serum was the strongest NIVEA face care rollout in history

    80% confidence
  • The global skincare market slowed materially, decelerating from mid-single-digit growth in 2024 to roughly 1.5% to 2% in 2025

    80% confidence
  • India, domestic China and Japan were cited as white spaces for Derma expansion

    80% confidence
  • The shift is primarily a reallocation of spending away from premium face care into body care, deodorants and affordable skincare, which are much less media intensive

    80% confidence
  • Market dynamics had not improved at the start of 2026

    80% confidence
  • Beiersdorf would not reduce marketing investment proportionally despite margin pressure

    80% confidence
  • Employee safety was the top priority regarding Middle East volatility and it was too early to assess any potential business impact

    80% confidence
  • Beiersdorf delivered stable full-year 2025 results in a difficult operating backdrop

    80% confidence
  • La Prairie's Q1 2026 performance would be down double digits

    80% confidence
  • Eucerin Thiamidol Serum became the number one derma anti-pigment serum in China

    80% confidence
  • Consumers became more cautious and increasingly selective in their routines

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com